Introduction
============

Neuroblastoma is a commonly occurring pediatric tumor derived from the embryonic neural crest [@B1]. Neuroblastoma is the fourth most frequently occurring tumor among Chinese children with an incidence of 7.7 cases per million [@B2]. While low- and intermediate-risk patients may have a good prognosis, high-risk neuroblastoma is still difficult to cure. Approximately 40% of patients are high-risk and have poor outcomes [@B3], [@B4]. Potential risk factors for children developing neuroblastoma include parental exposure to wood dust, radiation sources, solders, and hydrocarbons, though the reasons are incompletely understood [@B5], [@B6]. Genetic factors (e.g., mutations and polymorphisms) may also play an important role in the occurrence of neuroblastoma [@B7]-[@B11]. For instance, *FAS*/*FASL* gene polymorphisms has been shown to confer neuroblastoma risk in Chinese children [@B12]. Low-frequency variants may also contribute to tumorigenesis including neuroblastoma [@B13], [@B14].

The *LIM domain only 1* (*LMO1*) gene located at the 11p15 region encodes an intertwining LIM-only transcriptional regulator [@B15]. The LMO1 protein is implicated in the initiation and development of several cancers [@B16]. A genome-wide association study (GWAS) comprising 2,251 neuroblastoma cases and 6,097 controls of European ancestry identified four single nucleotide polymorphisms (SNPs) in the *LMO1* gene that were associated with neuroblastoma susceptibility [@B15]. None of the four polymorphisms (rs110419 A\>G, rs4758051 G\>A, rs10840002 A\>G and rs204938 A\>G) is a potentially functional polymorphism. In 2015, Oldridge*et al*. [@B17] identified a causal DNA variant (rs2168101 G\>T) in the *LMO1* gene that was significantly associated with decreased neuroblastoma susceptibility (combined *P*=7.47 x 10^-29^). To date, this association has not been verified among other ethnicities; therefore, we conducted the current two-center case-control study among a total of 374 neuroblastoma cases and 812 controls.

Materials and methods
=====================

Study subjects
--------------

This study was comprised of two independent retrospective hospital-based case-control studies (**Supplemental Table [1](#SM0){ref-type="supplementary-material"}**). The southern Chinese population study involved 256 neuroblastoma patients and 531 controls that were recruited from the Guangzhou Women and Children\'s Medical Center, as we described previously [@B18]-[@B20]. The northern Chinese population study involved 118 neuroblastoma patients and 281 controls that were recruited from the First Affiliated Hospital of Zhengzhou University between August 2011 and April 2017 [@B21], [@B22]. Briefly, all of the included cases were histopathologically diagnosed as new neuroblastoma patients. All of the included subjects provided written informed consent by their guardian. This study was authorized by the Institutional Review Board of each hospital.

Selection of polymorphisms and genotyping
-----------------------------------------

Five polymorphisms (rs2168101 G\>T, rs1042359 A\>G, rs11041838 G\>C, rs2071458 C\>A, and rs3750952 G\>C) in the *LMO1* gene were selected (**Supplemental Table [2](#SM0){ref-type="supplementary-material"}**). Of the five polymorphisms, the rs2168101 G\>T, rs1042359 A\>G, and rs3750952 G\>C polymorphisms were identified in a previous study [@B17]. We also chose rs11041838 G\>C and rs2071458 C\>A, which were potentially functional (Transcription factor binding site, TFBS) polymorphisms according to the online software SNPinfo (<https://snpinfo.niehs.nih.gov/>). Genomic DNA was primarily extracted from peripheral blood lymphocytes. All five selected polymorphisms were genotyped by the Taqman methodology, as described previously [@B23], [@B24]. At least 10% of the samples were randomly selected for further confirmation, and the results were 100% concordant [@B25]-[@B27].

Statistical analysis
--------------------

The Chi-square test was adopted to compare the frequency distribution of demographic variables and genotypes. The goodness-of-χ^2^ test was used to evaluate the Hardy-Weinberg equilibrium (HWE) for control subjects. Multivariate logistic regression was used to calculate the odds ratio (OR) and the 95% confidence interval (CI). We also calculated the false-positive report probability (FPRP) values for significant findings from the combined subjects, as we described previously [@B28], [@B29]. *P* values less than 0.05 were considered to be statistically significant findings.

Results
=======

Characteristics of subjects
---------------------------

As shown in **Supplemental Table [1](#SM0){ref-type="supplementary-material"}**, no significant difference was observed between cases and controls in age (*P*=0.239) or gender (*P*=0.333) for southern Chinese subjects. Similar findings were observed among the northern Chinese children (*P*=0.189 for age, and *P*=0.196 for gender).

*LMO1* gene polymorphisms and neuroblastoma susceptibility
----------------------------------------------------------

As shown in **Table [1](#T1){ref-type="table"}**, the genotype frequencies of the five selected polymorphisms did not deviate from the HWE in the combined controls (*P*=0.448 for rs2168101 G\>T, *P*=0.786 for rs1042359 A\>G, *P*=0.056 for rs11041838 G\>C, *P*=0.427 for rs2071458 C\>A, and *P*=0.886 for rs3750952 G\>C). Regarding the selected polymorphisms, after adjustment for age and gender, we observed that the rs2168101 G\>T polymorphism was significantly associated with decreased neuroblastoma risk for southern Chinese subjects (GT vs. GG: adjusted OR=0.62, 95% CI=0.45-0.86, *P*=0.004; TT vs. GG: adjusted OR=0.29, 95% CI=0.13-0.67, *P*=0.004; GT/TT vs. GG: adjusted OR=0.57, 95% CI=0.42-0.78, *P*=0.0004; and TT vs. GT/GG: adjusted OR=0.35, 95% CI=0.15-0.80, *P*=0.012), and for northern Chinese subjects (GT vs. GG: adjusted OR=0.45, 95% CI=0.28-0.73, *P*=0.001; TT vs. GG: adjusted OR=0.26, 95% CI=0.09-0.78, *P*=0.016; and GT/TT vs. GG: adjusted OR=0.42, 95% CI=0.27-0.66, *P*=0.0002). When we combined all subjects, the protective effect was more noteworthy (GT vs. GG: adjusted OR=0.57, 95% CI=0.44-0.74, *P*\<0.0001; TT vs. GG: adjusted OR=0.29, 95% CI=0.15-0.56, *P*=0.0002; GT/TT vs. GG: adjusted OR=0.53, 95% CI=0.41-0.68, *P*\<0.0001; and TT vs. GT/GG: adjusted OR=0.36, 95% CI=0.19-0.69, *P*=0.002), after adjustment for age and gender. Similar significant associations were found for the rs3750952 G\>C polymorphism for the southern, northern and combined subjects. When the protective genotypes were combined, we observed that the 2-5 protective genotype carriers had a significantly decreased neuroblastoma risk for southern (adjusted OR=0.68, 95% CI=0.50-0.92, *P*=0.012), northern (adjusted OR=0.53, 95% CI=0.34-0.83, *P*=0.005) and combined subjects (adjusted OR=0.62, 95% CI=0.49-0.80, *P*=0.0002), after adjustment for age and gender.

Stratified analysis
-------------------

The associations between rs2168101 G\>T, rs3750952 G\>C, and the combined protective genotypes with neuroblastoma susceptibility were further evaluated by stratification analysis for southern Chinese subjects (**Supplemental Table [3](#SM0){ref-type="supplementary-material"}**), northern Chinese subjects (**Supplemental Table [4](#SM0){ref-type="supplementary-material"}**), and combined subjects (**Table [2](#T2){ref-type="table"}**). For the rs2168101 G\>T polymorphism, the protective effect was prominent among children older than 18 months, males, females, tumors that originated from the adrenal gland and the mediastinum, and both the INSS stage I+II+4s, and stage III+IV subjects. A similar significant association was observed for the rs3750952 G\>C polymorphism and the combined protective genotypes.

FPRP analysis
-------------

The FPRP results for statistically significant findings from the combined subjects are shown in **Table [3](#T3){ref-type="table"}**. When we adopted a FPRP threshold of 0.2, as suggested by Wacholder *et al.* [@B30], we observed that all of the significant findings for the rs2168101 still remained noteworthy at the prior probability of 0.1, except for rs2168101 TT vs. GG/GT. Similar results were observed for rs3750952 G\>C, with exceptions of females, tumor origin from the adrenal gland and INSS stage I+II+4s. Regarding the combined protective genotypes, all of the significant findings were still noteworthy, except for males and tumor originated from the adrenal gland.

Discussion
==========

In the current two-center hospital-based case-control study, we confirmed that the *LMO1* gene rs2168101 G\>T and rs3750952 G\>C polymorphisms were significantly associated with decreased neuroblastoma risk for Chinese children from North and South China. To the best of our knowledge, this report describes the first replication study for the latest finding that the *LMO1* super-enhancer polymorphism rs2168101 G\>T was associated with a significantly decreased neuroblastoma risk.

The *LMO1* gene (gene ID: 4004) is located on chromosome 11 in the p15.4 region. *LMO1* encodes a cysteine-rich transcriptional regulator, which constitutes two LIM zinc-binding domains [@B31]. LMO1 belongs to the LMO family, which contains four superfamily numbers, LMO1 to LMO4 [@B31], [@B32]. LMO1 was reported to be mainly expressed in the nervous system and is involved in the development of the nervous system [@B33]. It is also reported to be highly expressed in the skin, testis, brain, adrenal and kidney tissues, as was determined through RNA-seq data performed with tissue samples derived from 95 individuals, representing 27 different tissues [@B34].

The *LMO1* gene contains at least 5,271 polymorphisms (<https://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?locusId=4004>). In 2011, Wang*et al*. [@B15] performed a large GWAS with 2,251 neuroblastoma patients and 6,097 controls. Four *LMO1* gene polymorphisms (rs110419 A\>G, rs4758051 G\>A, rs10840002 A\>G and rs204938 A\>G) were identified and were observed to be significantly associated with neuroblastoma susceptibility. The most significant association was with rs110419 A\>G (combined *P*=5.2 x 10^-16^). These researchers also observed that LMO1 depletion may inhibit the growth of neuroblastoma cells, whereas overexpression may lead to enhanced proliferation [@B15]. The association between these four polymorphisms and neuroblastoma susceptibility have been validated in African-Americans [@B35], Italians [@B36], and northern [@B37] and southern Chinese populations [@B18]. The study pertaining to the African-Americans investigated 390 neuroblastoma cases and 2,500 controls. However, in this study, Latorre*et al*. [@B35] found that none of these four polymorphisms was associated with neuroblastoma susceptibility. In the study conducted by Capasso*et al*. [@B36], 370 cases and 809 controls from Italy were investigated, and it was observed that the rs110419 A\>G polymorphism was associated with neuroblastoma susceptibility. However, these researchers failed to verify the association between the rs4758051 G\>A polymorphism and neuroblastoma risk. In the study that investigated 244 patients and 305 controls from the northern Chinese population, Lu*et al*. [@B37] identified 11 polymorphisms within the *LMO1* gene that were associated with neuroblastoma susceptibility. The most prominent polymorphism was rs204926 T\>C (OR=0.45, 95% CI=0.31-0.65). In one of our previous publications, we included a total of 256 patients and 531 controls from South China to validate the association between these four polymorphisms (rs110419 A\>G, rs4758051 G\>A, rs10840002 A\>G and rs204938 A\>G) and neuroblastoma susceptibility, and we only verified that the rs110419 A\>G polymorphism was significantly associated with neuroblastoma susceptibility [@B18]. However, all these four polymorphisms were not functional.

At the end of 2015, Oldridge*et al*. [@B17] investigated the causal DNA variant in the *LMO1* gene and the possible mechanism by which the polymorphism may lead to neuroblastoma tumourigenesis. All possible genotypes within the *LMO1* gene were determined, and highly associated polymorphisms were categorized based on chromatin accessibility and evolutionary conservation, as well as transcription factor binding site areas. These researchers observed that the *LMO1* rs2168101 G\>T polymorphism located at the first intron was the most highly associated variant (combined *P*=7.47 x 10^-29^). This polymorphism was located in a super-enhancer defined by extensive acetylation of histone H3 lysine 27. The *LMO1* rs2168101 G allele was associated with tumor formation, a decreased event-free survival and overall survival in the European-American subjects. This association was not replicated in any other race or centers to date. We conducted the current study with neuroblastoma patients from both northern and southern Chinese populations. We verified that both the *LMO1* rs2168101 G\>T and rs3750952 G\>C polymorphisms were significantly associated with decreased neuroblastoma susceptibility, a finding similar to that of Oldridge*et al*. [@B17]. This result indicates that the roles of these two polymorphisms are not limited to ethnicity.

Though this report describes the first replication study involving neuroblastoma patients from both North and South China, several limitations should be noted. First, although we included neuroblastoma patients from two medical centers, the sample size is still relatively small with 374 cases and 812 controls. This sample size is mainly due to the availability of samples and the low occurrence rate of neuroblastoma. Larger multinational/muticenter studies were encouraged to validate the findings. Second, only five potentially functional polymorphisms were investigated in the current study. More polymorphisms should be evaluated. Finally, due to the limitation of retrospective studies, several important factors, such as the parents\' exposure to several environmental factors (e.g., wood dust, radiation sources, solders, and hydrocarbons), as well as the children\'s dietary intakes, were not available and adjusted for.

In summary, this study\'s results confirmed that the *LMO1* gene rs2168101 G\>T and rs3750952 G\>C polymorphisms were associated with decreased neuroblastoma risk. These findings must be further validated through multi-center studies with large sample sizes and different ethnicities.
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###### 

Genotype frequencies of *LMO1* gene polymorphisms and neuroblastoma susceptibility

  Genotype                                      Guangdong province   Henan province   Combined                                                                                                                                               
  --------------------------------------------- -------------------- ---------------- ---------------------- ------------ ------------- ------------- ---------------------- ------------ ------------- ------------- ---------------------- --------------
  rs2168101 G\>T (HWE=0.670)                    HWE=0.462            HWE=0.448                                                                                                                                                               
  GG                                            166 (65.10)          275 (51.79)      1.00                                79 (66.95)    132 (46.98)   1.00                                245 (65.68)   407 (50.12)   1.00                   
  GT                                            82 (32.16)           217 (40.87)      **0.62 (0.45-0.86)**   **0.004**    35 (29.66)    125 (44.48)   **0.45 (0.28-0.73)**   **0.001**    117 (31.37)   342 (42.12)   **0.57 (0.44-0.74)**   **\<0.0001**
  TT                                            7 (2.75)             39 (7.34)        **0.29 (0.13-0.67)**   **0.004**    4 (3.39)      24 (8.54)     **0.26 (0.09-0.78)**   **0.016**    11 (2.95)     63 (7.76)     **0.29 (0.15-0.56)**   **0.0002**
  Additive                                                                            **0.59 (0.45-0.77)**   **0.0001**                               **0.47 (0.32-0.70)**   **0.0002**                               **0.56 (0.45-0.69)**   **\<0.0001**
  Dominant                                      89 (34.90)           256 (48.21)      **0.57 (0.42-0.78)**   **0.0004**   39 (33.05)    149 (53.02)   **0.42 (0.27-0.66)**   **0.0002**   128 (34.32)   405 (49.88)   **0.53 (0.41-0.68)**   **\<0.0001**
  Recessive                                     248 (97.25)          492 (92.66)      **0.35 (0.15-0.80)**   **0.012**    114 (96.61)   257 (91.46)   0.36 (0.12-1.05)       0.062        362 (97.05)   749 (92.24)   **0.36 (0.19-0.69)**   **0.002**
  rs1042359 A\>G (HWE=0.065)                    HWE=0.199            HWE=0.786                                                                                                                                                               
  AA                                            233 (91.37)          485 (91.34)      1.00                                97 (82.20)    224 (79.72)   1.00                                330 (88.47)   709 (87.32)   1.00                   
  AG                                            21 (8.24)            43 (8.10)        1.02 (0.60-1.76)       0.947        20 (16.95)    56 (19.93)    0.82 (0.47-1.44)       0.491        41 (10.99)    99 (12.19)    0.89 (0.60-1.31)       0.547
  GG                                            1 (0.39)             3 (0.56)         0.69 (0.07-6.70)       0.750        1 (0.85)      1 (0.36)      2.26 (0.14-36.68)      0.567        2 (0.54)      4 (0.49)      1.08 (0.20-5.94)       0.928
  Additive                                                                            0.98 (0.60-1.60)       0.933                                    0.88 (0.52-1.50)       0.643                                    0.91 (0.64-1.30)       0.606
  Dominant                                      22 (8.63)            46 (8.66)        1.00 (0.59-1.70)       0.992        21 (17.80)    57 (20.28)    0.85 (0.49-1.47)       0.554        43 (11.53)    103 (12.68)   0.90 (0.61-1.31)       0.568
  Recessive                                     254 (99.61)          528 (99.44)      0.69 (0.07-6.68)       0.749        117 (99.15)   280 (99.64)   2.34 (0.14-37.99)      0.550        371 (99.46)   808 (99.51)   1.10 (0.20-6.02)       0.915
  rs11041838 G\>C (HWE=0.448)                   HWE=0.031            HWE=0.056                                                                                                                                                               
  GG                                            175 (68.63)          386 (72.69)      1.00                                85 (72.03)    196 (69.75)   1.00                                260 (69.71)   582 (71.67)   1.00                   
  GC                                            74 (29.02)           136 (25.61)      1.20 (0.86-1.68)       0.290        31 (26.27)    83 (29.54)    0.88 (0.54-1.44)       0.614        105 (28.15)   219 (26.97)   1.08 (0.82-1.42)       0.608
  CC                                            6 (2.35)             9 (1.69)         1.46 (0.51-4.18)       0.478        2 (1.69)      2 (0.71)      2.19 (0.30-16.01)      0.440        8 (2.14)      11 (1.35)     1.62 (0.65-4.08)       0.304
  Additive                                                                            1.20 (0.90-1.61)       0.221                                    0.96 (0.61-1.51)       0.867                                    1.12 (0.88-1.43)       0.370
  Dominant                                      80 (31.37)           145 (27.31)      1.22 (0.88-1.68)       0.243        33 (27.97)    85 (30.25)    0.92 (0.57-1.48)       0.719        113 (30.29)   230 (28.33)   1.10 (0.84-1.44)       0.483
  Recessive                                     249 (97.65)          522 (98.31)      1.39 (0.49-3.95)       0.536        116 (98.31)   279 (99.29)   2.26 (0.31-16.46)      0.421        365 (97.86)   801 (98.65)   1.59 (0.63-3.99)       0.323
  rs2071458 C\>A (HWE=0.911)                    HWE=0.320            HWE=0.427                                                                                                                                                               
  CC                                            160 (62.75)          324 (61.02)      1.00                                70 (59.32)    155 (55.16)   1.00                                230 (61.66)   479 (58.99)   1.00                   
  CA                                            81 (31.76)           181 (34.09)      0.91 (0.66-1.25)       0.551        42 (35.59)    103 (36.65)   0.92 (0.58-1.46)       0.736        123 (32.98)   284 (34.98)   0.90 (0.69-1.17)       0.439
  AA                                            14 (5.49)            26 (4.90)        1.13 (0.57-2.22)       0.733        6 (5.08)      23 (8.19)     0.58 (0.23-1.50)       0.264        20 (5.36)     49 (6.03)     0.85 (0.49-1.47)       0.560
  Additive                                                                            0.98 (0.76-1.26)       0.843                                    0.84 (0.59-1.19)       0.331                                    0.91 (0.74-1.12)       0.375
  Dominant                                      95 (37.25)           207 (38.98)      0.93 (0.69-1.27)       0.661        48 (40.68)    126 (44.84)   0.86 (0.56-1.34)       0.504        143 (38.34)   333 (41.01)   0.89 (0.70-1.15)       0.381
  Recessive                                     241 (94.51)          505 (95.10)      1.17 (0.60-2.28)       0.656        112 (94.92)   258 (91.81)   0.60 (0.24-1.52)       0.283        353 (94.64)   763 (93.97)   0.88 (0.52-1.51)       0.649
  rs3750952 G\>C (HWE=0.994)                    HWE=0.763            HWE=0.886                                                                                                                                                               
  GG                                            147 (57.65)          253 (47.65)      1.00                                65 (55.08)    120 (42.70)   1.00                                212 (56.84)   373 (45.94)   1.00                   
  GC                                            100 (39.22)          227 (42.75)      **0.76 (0.56-1.03)**   **0.081**    47 (39.83)    129 (45.91)   **0.66 (0.42-1.03)**   **0.069**    147 (39.41)   356 (43.84)   **0.73 (0.56-0.94)**   **0.014**
  CC                                            8 (3.14)             51 (9.60)        **0.27 (0.12-0.58)**   **0.0008**   6 (5.08)      32 (11.39)    **0.32 (0.13-0.81)**   **0.017**    14 (3.75)     83 (10.22)    **0.30 (0.16-0.53)**   **\<0.0001**
  Additive                                                                            **0.65 (0.50-0.83)**   **0.0006**                               **0.61 (0.43-0.87)**   **0.006**                                **0.64 (0.52-0.78)**   **\<0.0001**
  Dominant                                      108 (42.35)          278 (52.35)      **0.67 (0.49-0.90)**   **0.008**    53 (44.92)    161 (57.30)   **0.59 (0.38-0.91)**   **0.018**    161 (43.16)   439 (54.06)   **0.65 (0.50-0.83)**   **0.0005**
  Recessive                                     247 (96.86)          480 (90.40)      **0.30 (0.14-0.64)**   **0.002**    112 (94.92)   249 (88.61)   **0.39 (0.16-0.97)**   **0.043**    359 (96.25)   729 (89.78)   **0.34 (0.19-0.61)**   **0.0003**
  Combined effect of protective genotypes ^c^                                                                                                                                                                                                
  0-1                                           129 (50.59)          218 (41.05)      1.00                                55 (46.61)    89 (31.67)    1.00                                184 (49.33)   307 (37.81)   1.00                   
  2-5                                           126 (49.41)          313 (58.95)      **0.68 (0.50-0.92)**   **0.012**    63 (53.39)    192 (68.33)   **0.53 (0.34-0.83)**   **0.005**    189 (50.67)   505 (62.19)   **0.62 (0.49-0.80)**   **0.0002**

OR, odds ratio; CI, confidence interval, HWE, Hardy-Weinberg equilibrium.

^a^ *χ^2^* test for genotype distributions between neuroblastoma patients and controls.

^b^ Adjusted for age and gender.

^c^ Protective genotypes that reduced neuroblastoma risk were rs2168101 GT/TT, rs1042359 AG/GG, rs11041838 GG, rs2071458 CA/AA, and rs3750952 GC/CC.

###### 

Stratification analysis for the association between *LMO1* gene polymorphisms and neuroblastoma susceptibility (combined subjects)

  Variables         rs2168101 G\>T   rs3750952 G\>C   Protective genotypes ^a^                                                                                                                     
  ----------------- ---------------- ---------------- -------------------------- -------------- --------- --------- ---------------------- ------------ --------- --------- ---------------------- --------------
  Age, month                                                                                                                                                                                       
  ≤18               77/158           47/147           0.65 (0.43-1.00)           0.052          64/146    60/159    0.86 (0.57-1.31)       0.477        58/118    66/187    0.72 (0.47-1.09)       0.123
  \>18              168/249          81/258           **0.46 (0.34-0.64)**       **\<0.0001**   148/227   101/280   **0.55 (0.40-0.75)**   **0.0001**   126/189   123/318   **0.58 (0.43-0.79)**   **0.0005**
  Gender                                                                                                                                                                                           
  Females           107/166          50/176           **0.44 (0.30-0.66)**       **\<0.0001**   88/152    69/190    **0.63 (0.43-0.92)**   **0.018**    81/127    76/215    **0.56 (0.38-0.81)**   **0.003**
  Males             138/241          78/229           **0.60 (0.43-0.83)**       **0.002**      124/221   92/249    **0.66 (0.48-0.92)**   **0.013**    103/180   113/290   **0.68 (0.49-0.94)**   **0.021**
  Sites of origin                                                                                                                                                                                  
  Adrenal gland     95/407           39/405           **0.41 (0.28-0.61)**       **\<0.0001**   77/373    57/439    **0.63 (0.43-0.91)**   **0.013**    63/307    71/505    **0.68 (0.47-0.99)**   **0.044**
  Retroperitoneal   53/407           34/405           0.65 (0.41-1.02)           0.063          43/373    44/439    0.88 (0.56-1.37)       0.566        38/307    49/505    0.79 (0.51-1.24)       0.300
  Mediastinum       74/407           35/405           **0.48 (0.31-0.73)**       **0.0006**     71/373    38/439    **0.46 (0.30-0.69)**   **0.0002**   67/307    42/505    **0.38 (0.25-0.58)**   **\<0.0001**
  Others            21/407           14/405           0.67 (0.34-1.34)           0.259          18/373    17/439    0.81 (0.41-1.59)       0.535        14/307    21/505    0.91 (0.46-1.82)       0.796
  Clinical stages                                                                                                                                                                                  
  I+II+4s           103/407          61/405           **0.60 (0.42-0.84)**       **0.003**      90/373    74/439    **0.70 (0.50-0.98)**   **0.036**    81/307    83/505    **0.62 (0.44-0.87)**   **0.006**
  III+IV            127/407          62/405           **0.48 (0.35-0.68)**       **\<0.0001**   110/373   79/439    **0.60 (0.44-0.83)**   **0.002**    91/307    98/505    **0.65 (0.47-0.89)**   **0.008**

OR, odds ratio; CI, confidence interval.

^a^ Protective genotypes that decreased neuroblastoma risk were rs2168101 GT/TT, rs1042359 AG/GG, rs11041838 GG, rs2071458 CA/AA, and rs3750952 GC/CC.

^b^ Adjusted for age and gender, omitting the corresponding stratification factor.

###### 

False-positive report probability results for outstanding findings in combined subjects

  ------------------------------------------------------------------------------------------------------------------------------------------
  Genotype         Crude OR\          *P* ^a^    Statistical power ^b^   Prior probability                                       
                   (95% CI)                                                                                                      
  ---------------- ------------------ ---------- ----------------------- ------------------- ----------- ----------- ----------- -----------
  rs2168101 G\>T                                                                                                                 

  GT vs. GG        0.57 (0.44-0.74)   \<0.0001   0.122                   **0.001**           **0.002**   **0.020**   **0.170**   0.672

  TT vs. GG        0.29 (0.15-0.56)   0.0002     0.009                   **0.060**           **0.160**   0.677       0.955       0.995

  GT/TT vs. GG     0.53 (0.41-0.68)   \<0.0001   0.034                   **0.000**           **0.000**   **0.002**   **0.020**   **0.166**

  TT vs. GG/GT     0.36 (0.19-0.69)   0.0022     0.050                   **0.117**           0.284       0.814       0.978       0.998

  GT/TT vs. GG                                                                                                                   

  \>18             0.47 (0.34-0.64)   \<0.0001   0.015                   **0.000**           **0.001**   **0.016**   **0.137**   0.614

  Females          0.44 (0.30-0.66)   \<0.0001   0.023                   **0.007**           **0.021**   **0.188**   0.700       0.959

  Males            0.60 (0.43-0.83)   00.0021    0.247                   **0.025**           **0.071**   0.457       0.895       0.988

  Adrenal gland    0.41 (0.28-0.61)   \<0.0001   0.011                   **0.003**           **0.010**   **0.100**   0.529       0.918

  Mediastinum      0.48 (0.31-0.73)   0.0006     0.065                   **0.027**           **0.078**   0.482       0.904       0.989

  I+II+4s          0.60 (0.42-0.84)   0.0032     0.258                   **0.036**           **0.100**   0.551       0.925       0.992

  III+IV           0.49 (0.35-0.69)   \<0.0001   0.039                   **0.002**           **0.007**   **0.068**   0.422       0.880

  rs3750952 G\>C                                                                                                                 

  GC vs. GG        0.73 (0.56-0.94)   0.0143     0.743                   **0.055**           **0.148**   0.656       0.951       0.995

  CC vs. GG        0.30 (0.16-0.54)   \<0.0001   0.007                   **0.023**           **0.065**   0.434       0.886       0.987

  GC/CC vs. GG     0.65 (0.50-0.83)   0.0005     0.387                   **0.004**           **0.012**   **0.116**   0.569       0.930

  CC vs. GG/GC     0.34 (0.19-0.61)   0.0003     0.022                   **0.038**           **0.107**   0.567       0.930       0.993

  GC/CC vs. GG                                                                                                                   

  \>18             0.55 (0.41-0.75)   0.0002     0.118                   **0.004**           **0.013**   **0.124**   0.589       0.935

  Females          0.63 (0.43-0.92)   0.0163     0.370                   **0.117**           0.284       0.813       0.978       0.998

  Males            0.66 (0.48-0.91)   0.0117     0.461                   **0.071**           **0.186**   0.715       0.962       0.996

  Adrenal gland    0.63 (0.44-0.91)   0.0138     0.374                   **0.100**           0.249       0.785       0.974       0.997

  Mediastinum      0.46 (0.30-0.69)   0.0002     0.040                   **0.016**           **0.046**   0.345       0.841       0.982

  I+II+4s          0.70 (0.50-0.98)   0.037      0.598                   **0.157**           0.358       0.860       0.984       0.998

  III+IV           0.61 (0.44-0.84)   0.0025     0.290                   **0.025**           **0.072**   0.461       0.896       0.989

  2-5 vs. 0-1      0.62 (0.49-0.80)   0.0002     0.294                   **0.002**           **0.006**   **0.063**   0.403       0.871

  \>18             0.58 (0.43-0.79)   0.0005     0.184                   **0.008**           **0.025**   0.220       0.740       0.966

  Females          0.55 (0.38-0.81)   0.0025     0.168                   **0.042**           **0.117**   0.593       0.936       0.993

  Males            0.68 (0.49-0.94)   0.0206     0.542                   **0.103**           0.256       0.791       0.974       0.997

  Adrenal gland    0.69 (0.47-0.99)   0.0438     0.551                   **0.193**           0.418       0.888       0.988       0.999

  Mediastinum      0.38 (0.25-0.58)   \<0.0001   0.005                   **0.003**           **0.008**   **0.080**   0.466       0.897

  I+II+4s          0.62 (0.45-0.87)   0.0060     0.341                   **0.050**           **0.136**   0.634       0.946       0.994

  III+IV           0.66 (0.48-0.90)   0.0092     0.446                   **0.057**           **0.155**   0.668       0.953       0.995
  ------------------------------------------------------------------------------------------------------------------------------------------

OR, odds ratio; CI, confidence interval.

^a^ Chi-square test was used to calculate the genotype frequency distributions.

^b^ Statistical power was calculated using the number of observations in the subgroup and the OR and *P* values in this table.
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